Mariska Sie

Mariska Sie

Auto-generated profile, based on publicly available information

Mariska Sie

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
RBRobin M. Bouttelgier
Robin M. Bouttelgier
MSMariska Sie
Mariska Sie
GHGiorgio G. Hallaert
Giorgio G. Hallaert

10 August 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
MSMariska Sie
Mariska Sie
OROscar H J Eelkman Rooda
Oscar H J Eelkman Rooda
MKMariette Kranendonk
Mariette Kranendonk
PWPieter Wesseling
Pieter Wesseling
MPMarc Pagès-Gallego
Marc Pagès-Gallego
EHEelco W Hoving
Eelco W Hoving
Background: Central nervous system (CNS) tumors represent the leading cause of pediatric cancer-related deaths. Primary treatment often involves neurosurgical tumor resection. Accurate diagnosis is crucial to perform the best-suited extent of resection. Recently, we published Sturgeon, an AI-based validated intraoperative nanopore sequencing tool, delivering accurate methylation-based diagnoses during surgery. Although several other nanopore sequencing strategies have been described, clear evidence of clinical impact remains critically absent. Here, we report a care evaluation analyzing the impact of Sturgeon on real-time pediatric neurosurgical decision-making. Methods: Since May 2023, a dual diagnostic neuro-oncological workflow incorporating intraoperative frozen section analyses and ultra-fast nanopore sequencing using Sturgeon has been fully implemented as standard of care at the Princess Máxima Center for Pediatric Oncology in the Netherlands. This intraoperative diagnostic workflow has been applied to all pediatric patients (<19 years of age) with primary CNS tumors and the multidisciplinary indication for tumor resection surgery. Results: Sturgeon delivered correct diagnoses in 82 out of 94 consecutive patients (87.2%, <90 minutes), no diagnosis in 11.7% and one incorrect diagnosis (1.1%). The diagnosis obtained by Sturgeon supported the intended surgical strategy (85.7%) or changed the strategy (14.3%) toward a more aggressive or limited resection. This contributed to a low complication rate and less second-look surgeries. Earlier communication of the histomolecular diagnosis to patients and their families was observed. Conclusions: Intraoperative use of Sturgeon provides essential guidance toward the most optimal neurosurgical strategy for pediatric CNS tumors and thereby has great potential to contribute to better clinical outcome.

29 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MSMariska Sie
Mariska Sie
OROscar H.J. Eelkman Rooda
Oscar H.J. Eelkman Rooda
MKMariette Kranendonk
Mariette Kranendonk
PWPieter Wesseling
Pieter Wesseling
MPMarc Pagès-Gallego
Marc Pagès-Gallego
EHEelco W. Hoving
Eelco W. Hoving
For pediatric patients with central nervous system (CNS) tumors, primary treatment often involves neurosurgical tumor resection. Accurate diagnosis is crucial to perform the best-suited extent of resection. Since two years, Sturgeon, an AI-based validated intraoperative nanopore sequencing tool, has been fully integrated with frozen section analyses as standard of care in our nationwide centralized pediatric oncology hospital. This care evaluation is the first to demonstrate the impact of Sturgeon on neurosurgical decision-making. Sturgeon delivered correct diagnoses in 82 out of 94 consecutive patients (87.2%, <90 minutes), no diagnosis in 11.7% and 1 incorrect diagnosis. The diagnosis obtained by Sturgeon supported the intended surgical strategy (85.7%) or changed the strategy (14.3%) toward a more aggressive or limited resection. This resulted in only 3.2% second-look surgeries. In conclusion, intraoperative use of Sturgeon provides essential guidance toward the most optimal neurosurgical strategy and thereby has great potential to contribute to better clinical outcome.

13 November 2025 in Operative Neurosurgery
Verified
Journal Article
Closed access
KGKevin Klein Gunnewiek
Kevin Klein Gunnewiek
SESander J. E. Eggermont
Sander J. E. Eggermont
ETEmma E. Trouw
Emma E. Trouw
MSMariska Sie
Mariska Sie
OROscar H. J. Eelkman Rooda
Oscar H. J. Eelkman Rooda
EHEelco W. Hoving
Eelco W. Hoving
BACKGROUND AND OBJECTIVES: Intraoperative ultrasound (iUS) is increasingly used in pediatric brain tumor surgery. However, accurate tumor tissue identification and localization within the patient with iUS remains challenging. Automatic tumor segmentation may overcome these difficulties by providing quicker, more consistent, and reliable image analysis. This study evaluated the feasibility of automatic 3-dimensional segmentation of pediatric brain tumors using navigated iUS. METHODS: A retrospective analysis was conducted on 109 navigated iUS acquisitions from 60 pediatric patients who underwent neurosurgical tumor resection. 3-dimensional nnU-Net was trained on 79 preresectional iUS acquisitions with corresponding tumor segmentations. Evaluation was performed on 30 iUS acquisitions against segmentations validated by 2 neurosurgeons. Performance benchmarks were set at a minimum Dice Similarity Coefficient (DSC) of 0.85 and a maximum mean surface distance and 95th percentile Hausdorff distance of 5 mm. RESULTS: The trained algorithm predicted tumor segmentations for all acquisitions in the test set, which met the predefined benchmark values with a median DSC of 0.89 (IQR: 0.13), a median mean surface distance of 1.1 mm (IQR: 1.0 mm), and a median 95th percentile Hausdorff distance of 5.6 mm (IQR: 3.5 mm). The lowest quartile of DSC values consisted of 5 patients, including craniopharyngiomas (n = 3) and high-grade gliomas (n = 2). Oversegmentation of the lateral ventricle as tumor was observed in 2 patients. In 1 high-grade glioma case, edema was misclassified as tumor because of unclear tumor boundaries. CONCLUSION: This study demonstrates that automatic segmentation of pediatric brain tumors using navigated iUS is feasible and achieved high performance in most cases, with few outliers that showed moderate performance in tumor prediction. Future efforts will focus on real-time segmentation of residual tumor tissue during tumor resection. Ultimately, real-time visualization of automatically segmented tumors in 3 dimensions could improve intraoperative navigation and support neurosurgical decision making.

21 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
CVC. Vermeulen
C. Vermeulen
HEH. van der Ent
H. van der Ent
SMSilvana Maas
Silvana Maas
Eelke M BosEelke M Bos
Eelke M Bos
KCK. Cammel
K. Cammel
JRJeroen de Ridder
Jeroen de Ridder
DNA methylation-based classification is increasingly a cornerstone of CNS tumor diagnostics. Recently,nanopore sequencing enables very rapid methylation profiling to support surgical decision making. Time-constrained sequencing yields sparse methylation profiles, necessitating specialized classifiers for accurate predictions. All publicly available sparse-profile classifiers rely on a single reference set of only 2,801 samples published in 2018 and its accompanying classification system. Here we present Sturgeon V2, trained on nearly 10,000 methylation profiles assembled from a range of public repositories and collaborations. To harmonize differences in tumor class labels, we developed an iterative semi-supervised relabeling strategy with a two-tiered concordance filter. We demonstrate that this filtering is essential for optimal performance. Compared to Sturgeon V1, we further redesigned the classifier architecture to provide more stable, and consistent confidence estimates while accumulating sequencing data and we introduce an updated class system including new classes, such as meningioma subtypes, PATZ-fusion neuroepithelial tumors and PLAG1/2-amplified embryonal tumors. In a retrospective intraoperative cohort of 94 pediatric cases, Sturgeon V2 was confidently correct in 85 cases (Sturgeon V1: 78) with one confident misclassification, and in simulated sequencing runs (n=1880) reduced the error rate among confident calls from 7.1% to 2.8%, outperforming publicly available alternatives. Sturgeon V2 is the first openly available, locally executable classifier for sparse methylation profiles trained beyond the 2018 reference era.